• Volition has recently engaged in active commercial discussions with significant players in the liquid biopsy, IVD, sepsis and oncology space.• Volition is actively preparing Data Rooms for potential near-term licensing opportunities in our two distinct disease areas: cancer and sepsis.• We have also made significant progress in readying our Nu.Q® NETs product for sepsis, Nu.Q® Lung Cancer and Capture-PCRTM technologies for licensing. We have a large amount of study data that we expect is close to being ready for inclusion in the data rooms and we have received expressions of interest from key industry players

After 28 months as Life Cycle Leader, I have recently changed position, with the aim of monetizing Volition IP and Mature Products through Distributorship and Out-licensing Alliances. In addition, I am also responsible for strategic partnerships with key Collaborators, contributing to building the value proposition and validation of Volition's Products and Solutions

Sysmex Life science business unit is committed to personalized medicine and cancer management through four main areas:• Clinical Laboratories Solutions• Surgical Oncology• Pathology Laboratories Solutions o Instrumentation (microtomes, stainers, embedding stations) o Digital scanners and SW suites o Artificial intelligence solutions through exclusive partnerships• Cytogenetics & Molecular Genetics: o Inostics Digital PCR portfolio (OncoBEAM liquid Biopsy biomarkers) o CGH/Arrays : CytoSureTM product line o NGS panels : SureSeqTM and Plasma Safe Seq o FISH Probes : CytocellTM

Consultancy-based activity in projects related to biotech and IVD sectors.PPMc stands for Predictive and Personalized Medicine Consulting

Assets portfolio management consisting in active out-licensing activities.Negotiation and implementation of various strategic partnerships and set up of distributorship agreements.Marketing and business development activities with key customers in the Pharmaceutical and Cosmetic industries.Direct involvement in capital rising operations.Consortium project leader in predicitive and personalized medicine project tendered through ISI/OSEO initiatives program.

BioQuanta is a privately held biotechnology company specialized in biology and molecular modeling, Our expertise in these fields has enabled us to develop unique service platforms for the health sciences, cosmetics, and agro-sciences sectors. We also apply our know-how to developing new biomarkers and diagnostic kits for clinical biology.BioQuanta adopts a resolutely original and unique approach in terms of contribution to predictive and personalized medicine, thus concretizing our vision: “Deliver the right drug, to the right patient at the right dose ”. Thanks to an integrated and multidisciplinary approach, we bring concrete and efficient answers throughout the life cycle of molecules, from early discovery phases until drug prescription and treatment follow-up. The failures rate and their impact on the development costs are mainly related to toxicities that are revealed tardily. The combination of our two disruptive platforms MultiDIP® (in silico) and Mitoxis® (in vitro) makes it possible to improve very significantly the prediction of toxicity as well as the categorization of patients, two essential prerequisites with the implementation of an effective medicine personalized. Based on daily clinical biology practice at the Hospitals of Paris network (APHP), closeness to the patients and their clinicians constitute the source of inspiration, our approach is not only centered on a given pathology, but enables an holistic exploration of metabolomic variables, including mitochondrial dysfunctions and oxidative stress markers. In addition, by modeling pharmacological ADME parameters of any xenobiotic and by measuring its impact on the metabolism, our integrated offer is also addressing cosmetic and agrofood industries, as well as those concerned by REACH regulation.

During the last six months, my role has consisted in elaborating the strategy for our two activities: Service Platforms and Diagnostic Kits.

Business Development activities have been focusing on three major Projects entailing new technologies and assays to get implemented into routine diagnostics.Project N°1: introduction of a new disruptive multiplex PCR assay in sepsis: development of clinical marketing.Achievement: multicentric randomized clinical trial (involving 18 University Hospitals) funded by the French Ministery of Health in order to determine the clinical utility of the new test.Project N°2: development of HPV business through positioning of genotyping in the management of cervical cancer. Involment in EMEA Task Force team to set up best practice and design best suited strategy. Interaction with KOLs.Project N°3: cooperation Roche Pharma and Roche Diagnsotics in the field of hepatitis C. Project based on companion diagnostics approach or personalized medicine, based on liver fibrosis markers.

- Product portfolio development: in- and out- licensing in interface with R&D, affiliates and opinion leaders. International launch of novel markers (SHBG – NT-proBNP – hsCRP).- Coordination of international “integrated” marketing: global product/local adaptation: Scientific and Marketing Communication – Competitive intelligence – Business Plans – Relation with Key Opinion Leaders (Boards – Congresses).Business Turnover 2004: > 200 €million Cardiology - >150 €million Hormonology. GR:+25%.

- Marketing & tactical plans, as well as proactive involvement in business for strategic corporate accounts: creative leadership by demonstration to field force- Launch of innovative Clinical Chemistry instruments Portfolio: Cobas Integra 700 - Cobas Integra 400 - Cobas Integra 800. - Unique positioning of the systems to cover general Clinical Chemistry testing (ISEs, Subtrates & Enzymes) as well as specialty testing e.g. Specific proteins, TDMs and DATs.- French affiliate achieved Second market position after US in terms of total number of placements and Market Segment leader position in France.

- Sales of Diagnostic Systems in the field of Immunology, Clinical Chemistry - Specialty testing (Proteins, TDMs, DATs) and Molecular Diagnostics [PCR] (CT/NG - HIV and HCV ).- Implementation of action plans and proactive involvement in operational projects with marketing teams.- Leadership in total supplier strategies, in particular in the field of consolidation in hospital tenders.- Management of DMU (Decision Making Units) and multiple stakeholders in projects involving joint ventures between private labs starting process of mergers.- Achievement of yearly goals and budget- Achived N°1 Sales Manager position in 2007

- Sales of Clinical Chemistry instruments and reagents for private and hospitals.

- Sales Rep covering several disciplines: Microbiology, Clinical Chemistry, Immunology.